Clinical significance of homologous recombination deficiency score testing in endometrial Cancer.

ABSTRACT:

Background

Homologous recombination deficiency (HRD) score is related to chemotherapy response in some cancers, but its role in endometrial cancer in not known. We determined frequency and clinical significance of alterations in the HR pathway in endometrial cancer.

Methods

253 endometrioid endometrial adenocarcinoma (EEA) samples from two independent cohorts (discovery and replication) were tested for HRD score using the Myriad HRD assay, microsatellite instability (MSI) and tumor mutation burden (TMB) using a next generation sequencing assay. HRD scores were also generated on endometrial cancer cell lines and in vivo response to olaparib was assessed.

Results

ROC curves were employed to determine optimal cutoffs of HRD in relation to survival impact in endometrial c

SUBMITTER: Siedel JH 

PROVIDER: S-EPMC8538374 | biostudies-literature | 2021 Mar

REPOSITORIES: biostudies-literature